Acute Care
Some stroke patients may fear contracting the coronavirus, while others who are isolated may not be discovered quickly enough.
The treatment may reduce the risk to healthcare workers because it reduces the duration and quantity of viral shedding.
Gilead Sciences committed to supplying approximately 607,000 vials over the next six weeks to treat an estimated 78,000 hospitalized patients.
One promising candidate is remdesivir, a drug originally developed for Ebola, which the FDA has approved for emergency use during the pandemic.
The test could detect COVID-19 infections in about six out of 10 people, and was nearly perfect in determining when an infection wasn't present.
Patient and staff morale has improved following implementation of a personalized, virtual rounding program intended to foster connectedness.
The results aim to act as a "playbook" of sorts for leaders and administrators who are looking for better ways to keep their group properly trained.
A continuous cardiorespiratory monitor uses a much larger data set for an analysis of risk for a subacute, potentially catastrophic, illness.
Providers should seek ways to automate the process as much as possible to curtail the manual work involved.
Gene therapy delivered through the adeno-associated virus is likely the most attractive alternative treatment until a vaccine is produced.